Intelligence / Semaglutide

Semaglutide

Prescription Only
GLP-1 Agonist
Schedule
S4
Prescription Only
Enforcement
Tightening
Low Risk
Providers
12
Access: Clear
Key Facts
Schedule 4 - Prescription Only
GLP-1 receptor agonist
TGA-approved branded products available
Compounded versions under increased scrutiny
Import restrictions tightened February 2026

Overview

Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes management. It is available in Australia as branded products (Ozempic, Wegovy) and through compounding pharmacies. The TGA has increased regulatory scrutiny on compounded versions following supply shortages.

Australian Scheduling

Schedule 4 (Prescription Only). TGA-approved branded products are listed on the ARTG. Compounded semaglutide is available under pharmacy compounding exemptions. Import restrictions were tightened in February 2026.

Access Pathway

Available through telehealth clinics and compounding pharmacies. Branded versions (Ozempic, Wegovy) can be prescribed by any GP. Compounded versions are available through specialised providers but face increasing regulatory scrutiny.

Regulatory Notice

For informational purposes only. TGA scheduling may change without notice. All Schedule 4 peptides require a valid prescription from a registered Australian medical practitioner. This site does not sell, supply, or facilitate access to therapeutic goods. Data compiled from TGA SUSMP, public provider directories, and publicly available review platforms.

News & Updates20 items
Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity: A Living Clinical Guideline From the ACP
Ann Intern Med16 June 2026
Cost-Effectiveness of Pharmacologic Treatments in Adults With Overweight or Obesity: A Systematic Review for the ACP
Ann Intern Med16 June 2026
Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the ACP
Ann Intern Med16 June 2026
Semaglutide and Risk of Pancreatic Cancer: A Meta-Analysis of Randomised Trials
Diabetes Obes Metab15 June 2026
Weight Changes With Lower Doses of Semaglutide in Clinical Practice: Findings From Routine Care
Diabetes Obes Metab15 June 2026
The Effect of Semaglutide on Quality of Life in Adults With Overweight or Obesity
Diabetes Obes Metab15 June 2026
Electrospun Nanofiber Oral Thin Film Platform for Sublingual Peptide Delivery
Diabetes Obes Metab15 June 2026
GLP-1 Receptor Agonists in Aesthetic Surgery: A Narrative Review on Perioperative Management
Aesthetic Plast Surg15 June 2026
Semaglutide associated with 15% reduction in fracture incidence in T2D patients — ENDO 2026 abstract
ENDO 202614 June 2026
GLP-1-based therapy and ICD-10-documented heart failure or respiratory failure events in non-diabetic adults with rheumatoid arthritis and obesity: a TriNetX federated cohort study.
Clinical rheumatology11 June 2026
Clinical evidence of semaglutide for metabolic dysfunction-associated steatotic liver disease (MASLD): An updated meta-analysis.
British journal of clinical pharmacology11 June 2026
Sustained Glycaemic Control and Preserved Beta-Cell Function in Newly Diagnosed Type 1 Diabetes Treated With Semaglutide.
Diabetes/metabolism research and reviews11 June 2026
GLP-1 receptor agonist adjunct therapy stabilises Ramadan dysglycaemia in insulin-treated diabetes: a CGM-based study.
Diabetes research and clinical practice10 June 2026
Wegovy pill (semaglutide 25 mg tablets) becomes first daily GLP-1 weight-loss pill approved in the UK
BioSpace10 June 2026
Semaglutide-induced loss of skeletal muscle mass is blunted by co-administration of ketone esters
JCI Insight9 June 2026
GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale — ADA 2026 symposium on semaglutide 25 mg, orforglipron, and lean-mass preservation
AJMC9 June 2026
Compounded medicines requirements clarified
Medical Republic8 June 2026
Early Generic Semaglutide in Canada — Implications for US Patients and Policy
JAMA Internal Medicine8 June 2026
Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain
Adv Ther6 June 2026
Steady-state pharmacokinetics of oral semaglutide using semi-mechanistic pharmacokinetic modelling and population simulations
Xenobiotica6 June 2026

Are You a Practitioner?

List your clinic for free and reach patients actively searching for legal peptide access in Australia.